Characterisation of seven medications approved for attention-deficit/hyperactivity disorder using in vitro models of hepatic metabolism

1. The metabolism of most medications approved for the treatment of ADHD is not fully understood.2. In vitro studies using cryopreserved, plated human hepatocytes (cPHHs) and pooled human liver microsomes (HLMs) were performed to more thoroughly characterise the metabolism of several ADHD medications.3. The use of enzyme-specific chemical inhibitors indicated a role for CYP2D6 in atomoxetine metabolism, and roles for CYP3A4/5 in guanfacine metabolism.4. The 4-hydroxy-atomoxetine and…

via https://pubmed.ncbi.nlm.nih.gov/36317558/?utm_source=no_user_agent&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20221107010905&v=2.17.8